Mankind Pharma reported strong Q2 FY27 results

Mankind Pharma reported strong Q2 FY27 results yesterday (Oct 26, 2026), with net profit rising nearly 38% year-on-year to ₹716 crore and revenue climbing 17.3% to ₹4,338 crore. The company’s stock surged 4.5% on the back of this performance, supported by robust demand in chronic therapies like cardiac and anti-diabetes drugs. 📊 Key Financial Highlights (Q2 FY27) Revenue from operations: ₹4,338 crore (up 17.3% YoY) Profit After Tax (PAT): ₹716 crore (up 37.7% YoY) EBITDA: ₹1,171–1,175 crore (up ~27% YoY) EBITDA margin: 27.1% (expanded by 210 basis points) Domestic revenue: ₹3,657 crore (up 14.8% YoY) International revenue: ₹681 crore (up 32.7% YoY) 🏥 Business Drivers Chronic therapies: Cardiac drugs grew ~19% Anti-diabetes drugs grew ~16% Gastroenterology up 19% Vitamins, minerals & nutrients (VMN) up 26% Consumer healthcare: Muted growth at 1.2% YoY, impacted by slower demand in OTC categories. International expansion: Revenue jumped 33%, supported by Bharat Serums & Vaccines (BSV) and new product launches in the U.S.